IL18 and neoplasm: In this case, Badn et al., demonstrated that a combination of low-dose CA4P and tumor immunization [like IL-18/Interferon-γ (IFNγ)] significantly enhances retardation of tumor growth as compared with either treatment alone and results in an enhanced antitumor immune reactivity (Badn et al., 2006).